Sierra Oncology Inc (SRRA)
Stock chart
Earnings
Value bought
Past 90 days
Value sold
Past 90 days
Net insiders buying
Past 90 days
Trades (buy and sell)
Past 90 days
Search
| Notification date | Transaction date | B/S Transaction type | Insider and/or position |
Nb. shares Price Value |
Number of shares | Price | Value | Details |
|---|---|---|---|---|---|---|---|---|
| 2022-04-07 | 2022-04-06 | PS Planned sale |
Chief Reg & Tech Ops Officer Officer |
6,347
-100.0%
37.25USD 236,409 |
6,347 -100.0% | 37.25 | USD 236,409 | |
| 2022-04-07 | 2022-04-05 | PS Planned sale |
Chief Reg & Tech Ops Officer Officer |
100
-100.0%
37.09USD 3,709 |
100 -100.0% | 37.09 | USD 3,709 | |
| 2022-04-04 | 2022-04-04 | PS Planned sale |
General Counsel, CCO & Sec'y Officer |
2,000
-100.0%
35.14USD 70,277 |
2,000 -100.0% | 35.14 | USD 70,277 | |
| 2022-03-22 | 2022-03-18 | PS Planned sale |
Chief Reg & Tech Ops Officer Officer |
100
-100.0%
37.05USD 3,705 |
100 -100.0% | 37.05 | USD 3,705 | |
| 2022-03-17 | 2022-03-17 | PS Planned sale |
Chief Reg & Tech Ops Officer Officer |
3,453
-100.0%
37.06USD 127,954 |
3,453 -100.0% | 37.06 | USD 127,954 | |
| 2022-03-04 | 2022-03-04 | PS Planned sale |
General Counsel, CCO & Sec'y Officer |
2,000
-100.0%
30.60USD 61,196 |
2,000 -100.0% | 30.60 | USD 61,196 | |
| 2022-02-08 | 2022-02-07 | PS Planned sale |
Chief Reg & Tech Ops Officer Officer |
10,000
-100.0%
32.32USD 323,225 |
10,000 -100.0% | 32.32 | USD 323,225 | |
| 2022-02-04 | 2022-02-04 | PS Planned sale |
General Counsel, CCO & Sec'y Officer |
2,000
-100.0%
29.78USD 59,560 |
2,000 -100.0% | 29.78 | USD 59,560 | |
| 2022-02-02 | 2022-02-02 | B Purchase |
Longitude Capital Partners III, LLC Large shareholder |
175,000
+inf%
27.00USD 4,725,000 |
175,000 +inf% | 27.00 | USD 4,725,000 | |
| 2022-02-02 | 2022-02-02 | B Purchase | Non-Executive Director Large shareholder |
175,000
+inf%
27.00USD 4,725,000 |
175,000 +inf% | 27.00 | USD 4,725,000 | |
| 2022-02-01 | 2022-01-31 | B Purchase | Non-Executive Director |
150,000
+12.9%
27.00USD 4,050,000 |
150,000 +12.9% | 27.00 | USD 4,050,000 | |
| 2022-02-01 | 2022-01-31 | B Purchase | Large shareholder |
150,000
+12.9%
27.00USD 4,050,000 |
150,000 +12.9% | 27.00 | USD 4,050,000 | |
| 2022-01-31 | 2022-01-31 | B Purchase | Non-Executive Director Large shareholder |
800,000
+41.3%
27.00USD 21,600,000 |
800,000 +41.3% | 27.00 | USD 21,600,000 | |
| 2022-01-31 | 2022-01-31 | B Purchase | Large shareholder |
800,000
+41.3%
27.00USD 21,600,000 |
800,000 +41.3% | 27.00 | USD 21,600,000 | |
| 2022-01-28 | 2022-01-26 | PS Planned sale |
Chief Reg & Tech Ops Officer Officer |
5,000
-100.0%
27.05USD 135,250 |
5,000 -100.0% | 27.05 | USD 135,250 | |
| 2022-01-28 | 2022-01-26 | PS Planned sale |
General Counsel & Secretary Officer |
2,000
-100.0%
29.00USD 58,000 |
2,000 -100.0% | 29.00 | USD 58,000 | |
| 2021-11-24 | 2021-11-24 | B Purchase | Non-Executive Director |
7,899
+141.0%
23.09USD 182,348 |
7,899 +141.0% | 23.09 | USD 182,348 | |
| 2021-11-24 | 2021-11-23 | B Purchase | Non-Executive Director |
5,601
+inf%
22.95USD 128,515 |
5,601 +inf% | 22.95 | USD 128,515 | |
| 2021-05-20 | 2021-05-19 | B Purchase |
CEO and President Executive Director |
5,000
+inf%
17.83USD 89,150 |
5,000 +inf% | 17.83 | USD 89,150 | |
| 2020-08-18 | 2020-08-18 | B Purchase |
Chief Development Officer Officer |
3,325
+198.5%
12.25USD 40,738 |
3,325 +198.5% | 12.25 | USD 40,738 | |
| 2020-08-18 | 2020-08-18 | B Purchase |
Chief Development Officer Officer |
5,950
+146.9%
12.22USD 72,710 |
5,950 +146.9% | 12.22 | USD 72,710 | |
| 2019-08-26 | 2019-08-23 | B Purchase |
Klencke Barbara Chief Development Officer Officer |
108,000
+200.0%
0.44USD 47,380 |
108,000 +200.0% | 0.44 | USD 47,380 | |
| 2019-08-26 | 2019-08-22 | B Purchase |
Klencke Barbara Chief Development Officer Officer |
54,000
+inf%
0.45USD 24,295 |
54,000 +inf% | 0.45 | USD 24,295 | |
| 2019-08-26 | 2019-08-22 | B Purchase |
Klencke Barbara Chief Development Officer Officer |
67,000
+inf%
0.43USD 28,964 |
67,000 +inf% | 0.43 | USD 28,964 | |
| 2018-12-11 | 2018-12-10 | B Purchase |
Allen Andrew R Non-Executive Director |
66,000
+inf%
1.64USD 108,240 |
66,000 +inf% | 1.64 | USD 108,240 | |
| 2017-03-09 | 2017-03-08 | B Purchase |
You Angie Chief Bus. & Strat. Officer |
30,000
+29.1%
1.43USD 42,900 |
30,000 +29.1% | 1.43 | USD 42,900 | |
| 2017-02-16 | 2017-02-14 | B Purchase |
Topper James N Large shareholder |
5,925,926
+inf%
1.35USD 8,000,000 |
5,925,926 +inf% | 1.35 | USD 8,000,000 | |
| 2016-03-24 | 2016-03-22 | PS Planned sale |
Chapman Wendy SVP Clinical Operations Officer |
3,000
-100.0%
7.01USD 21,023 |
3,000 -100.0% | 7.01 | USD 21,023 | |
| 2016-02-24 | 2016-02-22 | PS Planned sale |
Chapman Wendy SVP Clinical Operations Officer |
3,000
-100.0%
7.06USD 21,180 |
3,000 -100.0% | 7.06 | USD 21,180 | |
| 2016-01-25 | 2016-01-22 | PS Planned sale |
Chapman Wendy SVP Clinical Operations Officer |
5,000
-100.0%
9.39USD 46,973 |
5,000 -100.0% | 9.39 | USD 46,973 | |
| 2016-01-22 | 2016-01-22 | PS Planned sale |
Rodigueza Wendi Chief Scientific Officer Officer |
1,000
-0.6%
9.66USD 9,660 |
1,000 -0.6% | 9.66 | USD 9,660 | |
| 2016-01-22 | 2016-01-21 | PS Planned sale |
Rodigueza Wendi Chief Scientific Officer Officer |
1,000
-0.6%
10.32USD 10,323 |
1,000 -0.6% | 10.32 | USD 10,323 | |
| 2016-01-22 | 2016-01-20 | PS Planned sale |
Rodigueza Wendi Chief Scientific Officer Officer |
1,000
-0.6%
9.59USD 9,590 |
1,000 -0.6% | 9.59 | USD 9,590 | |
| 2016-01-19 | 2016-01-15 | PS Planned sale |
Glover Nicholas CEO and President Executive Director |
5,000
-100.0%
10.04USD 50,223 |
5,000 -100.0% | 10.04 | USD 50,223 | |
| 2016-01-14 | 2016-01-12 | PS Planned sale |
Lovejoy Chandra D SVP of Reg. Affairs & Quality Officer |
5,562
-100.0%
11.93USD 66,345 |
5,562 -100.0% | 11.93 | USD 66,345 | |
| 2016-01-14 | 2016-01-12 | PS Planned sale |
Lovejoy Chandra D SVP of Reg. Affairs & Quality Officer |
15,411
-73.5%
11.06USD 170,489 |
15,411 -73.5% | 11.06 | USD 170,489 | |
| 2015-07-21 | 2015-07-21 | B Purchase |
CHA ALBERT Non-Executive Director |
4,693
+0.2%
17.00USD 79,781 |
4,693 +0.2% | 17.00 | USD 79,781 | |
| 2015-07-21 | 2015-07-21 | B Purchase |
CHA ALBERT Non-Executive Director |
215,307
+9.7%
17.00USD 3,660,219 |
215,307 +9.7% | 17.00 | USD 3,660,219 | |
| 2015-07-21 | 2015-07-21 | B Purchase |
ORBIMED ADVISORS LLC Non-Executive Director |
175,000
+9.6%
17.00USD 2,975,000 |
175,000 +9.6% | 17.00 | USD 2,975,000 | |
| 2015-07-21 | 2015-07-21 | B Purchase |
Topper James N Non-Executive Director |
220,000
+11.2%
17.00USD 3,740,000 |
220,000 +11.2% | 17.00 | USD 3,740,000 | |
| 2015-07-21 | 2015-07-21 | B Purchase |
VIVO VENTURES VII, LLC Former 10% holder |
4,693
+0.2%
17.00USD 79,781 |
4,693 +0.2% | 17.00 | USD 79,781 | |
| 2015-07-21 | 2015-07-21 | B Purchase |
VIVO VENTURES VII, LLC Former 10% holder |
215,307
+9.7%
17.00USD 3,660,219 |
215,307 +9.7% | 17.00 | USD 3,660,219 | |
| 2015-07-21 | 2015-07-21 | B Purchase |
Thompson Peter A. Non-Executive Director |
175,000
+9.6%
17.00USD 2,975,000 |
175,000 +9.6% | 17.00 | USD 2,975,000 |